Back

Zigzag bipolar radiofrequency catheter ablation: a novel technique to achieve transmural lesions to eliminate ventricular arrhythmias

17 March 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Moderated ePosters 14: Best graded clinical cases. Unexpected challenges, complications and smart solutions for the interventional EP Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2019

About the speaker

Photo
Doctor Shingo Maeda

AOI Universal Hospital, Kawasaki (Japan)

5 More presentations in this session

Presentation thumbnail
Novel left parasternal epicardial access using a micropuncture kit
Doctor J. Behar (London, GB)
Abstract Slides
Presentation thumbnail
Early hyperbaric oxygen therapy for cerebral air embolism during atrial fibrillation ablation
Professor T. Ulus (Eskisehir, TR)
Presentation thumbnail
Bipolar radiofrequency ablation of parahisian premature ventricular contractions.
Doctor P. Futyma (Rzeszow, PL)
Abstract Slides
Presentation thumbnail
Transvenous or epimyocardial? How dizziness and palpitations can lead to tricuspid valve surgery 17 years after implantation of a transvenous pacemaker for congenital heart block
Doctor V. Rubesch-Kuetemeyer (Detmold, DE)
Abstract
Presentation thumbnail
Pacing above and beyond: single chamber atrial pacing in a patient with a Mustard procedure and superior baffle obstruction
Ms C. Lozano-Granero (Madrid, ES)
Abstract Slides

Access the full session

Session thumbnail
Moderated ePosters 14: Best graded clinical cases. Unexpected challenges, complications and smart solutions for the interventional EP

The Event

Event poster

EHRA 2019

17 March - 19 March 2019
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources